▟ Vinebot intrinsic value, daily

← back

BSX Boston Scientific

healthcare · valued with opus medium conviction · deep-dived 2026-10-09

STRONG BUY
Intrinsic value$48.43
Price (at call)$42.04
Margin of safety +15.2%
vs market (rating basis) +93.5%

PFA-and-Watchman compounder with margin room still to run; at $42, the market prices it like a plain med-tech.

⚠ defaulted drivers: horizon

The story

Boston Scientific is a diversified med-tech leader whose growth engine is electrophysiology (Farapulse pulsed-field ablation) and structural heart (Watchman), with steady contributions from endoscopy, urology and neuromodulation. Its moat is clinical data, physician training and switching costs in procedure-driven categories, refreshed by a disciplined tuck-in M&A program. It is in late high growth, compounding at mid-teens organically as PFA adoption broadens, and should slow toward a mature, high-single-digit and then GDP-like grower over the next decade.

Year-one growth of 12% sits below the 16.5% five-year CAGR because the Farapulse share gains are already in the base and competing PFA products are arriving. GAAP margin rises from about 20% toward 26% as amortization rolls off and mix and operating leverage improve, which puts it near peers like Stryker and below the adjusted margin of about 28%. The reported sales-to-capital of 0.58 is weighed down by acquisition goodwill, so I use 1.2 to reflect organic incremental reinvestment plus ongoing tuck-in deals.

Value drivers

Revenue growth (Y1)12.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin26.0%
Years to target margin6
Sales-to-capital1.20
Beta0.90
Failure probability1.0%
Cost of capital (WACC)8.8%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF31.25B
PV of terminal value49.23B
Equity value70.18B
÷ shares → per share$48.43

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 23.09B 12.0% 20.9% 4.12B 2.06B 2.06B 1.90B
2 25.64B 11.1% 21.9% 4.80B 2.13B 2.68B 2.26B
3 28.23B 10.1% 22.9% 5.53B 2.16B 3.37B 2.62B
4 30.82B 9.2% 24.0% 6.31B 2.16B 4.15B 2.97B
5 33.36B 8.2% 25.0% 7.12B 2.11B 5.01B 3.29B
6 35.78B 7.3% 26.0% 7.95B 2.02B 5.93B 3.58B
7 38.05B 6.3% 26.0% 8.45B 1.89B 6.56B 3.65B
8 40.10B 5.4% 26.0% 8.91B 1.71B 7.20B 3.68B
9 41.88B 4.4% 26.0% 9.30B 1.49B 7.82B 3.67B
10 43.35B 3.5% 26.0% 9.63B 1.22B 8.41B 3.63B

Key risks

  • PFA competition from Medtronic, J&J and Abbott compresses Farapulse share and pricing
  • Watchman growth slows if clinical data or reimbursement turn less favorable (e.g., OPTION/CHAMPION follow-through)
  • Acquisition overpayment or integration missteps erode returns on capital

Catalysts

  • Farapulse label expansions (persistent AF, first-line) and international PFA ramp
  • Watchman concomitant-procedure adoption and next-generation device launches

History

DatePriceIntrinsicMoSRating
2026-10-09$42.04 $48.43 +15.2% STRONG BUY
2026-08-20$52.01 $21.22 -59.2% HOLD
2026-06-30$43.48 $33.34 -23.3% STRONG BUY
2026-06-23$45.60 $35.54 -22.1% STRONG BUY